Perspectives in Care

1243 Latent Autoimmune Diabetes of Adults (LADA) Is Likely to Represent a Mixed Population of Autoimmune (Type 1) and Nonautoimmune (Type 2) Diabetes
  A.G. Jones, T.J. McDonald, B.M. Shields, W. Hagopian, and A.T. Hattersley

Commentary

1252 Glucagon-Like Peptide 1 Receptor Agonists, Carotid Atherosclerosis, and Cardiovascular Outcomes
  G. Marquis-Gravel and J.-C. Tardif

Clinical Care/Education/Nutrition/Psychosocial Research

1254 Frequency of Interruptions to Sitting Time: Benefits for Postprandial Metabolism in Type 2 Diabetes

1264 Spouse's Diabetes Status and Incidence of Depression and Anxiety: An 18-Year Prospective Study

Epidemiology/Health Services Research

1281 Diabetes and Overweight/Obesity Are Independent, Nonadditive Risk Factors for In-Hospital Severity of COVID-19: An International, Multicenter Retrospective Meta-analysis
  D.K. Longmore, J.E. Miller, S. Bekkering, C. Saner, E. Mifsud, L. Henkin, S. Saydah, and G. Wilkening, for the SEARCH for Diabetes in Youth Study Group

1291 Renal Replacement Therapy in People With and Without Diabetes in Germany, 2010–2016: An Analysis of More Than 25 Million Inhabitants
  H. Claessen, M. Narres, T. Kitkina, A. Wilk, H. Friedel, C. Günst er, M. Koch, K. Jandeleit-Dahm, and A. Jicks


1309 Genetic Risk Factors for CVD in Type 1 Diabetes: The DCCT/EDIC Study

1317 Incremental Dental Expenditures Associated With Diabetes Among Noninstitutionalized U.S. Adults Aged ≥18 Years Old in 2016–2017
  Y. Chen, P. Zhang, E.T. Luman, S.O. Griffin, and D.B. Rolka

Emerging Therapies: Drugs and Regimens

1324 Efficacy and Safety of Mulberry Twig Alkaloids Tablet for the Treatment of Type 2 Diabetes: A Multicenter, Randomized, Double-Blind, Double-Dummy, and Parallel Controlled Clinical Trial

1334 Effects of the SGLT2 Inhibitor Dapagliflozin on Energy Metabolism in Patients With Type 2 Diabetes: A Randomized, Double-Blind Crossover Trial

1344 Glucagon-Like Peptide 1 Receptor Agonists and Chronic Lower Respiratory Disease Exacerbations Among Patients With Type 2 Diabetes
  Y. Albogami, K. Cusi, M.J. Daniels, Y.-J.J. Wei, and A.G. Winterstein

1353 Feasibility of Simplification From a Basal-Bolus Insulin Regimen to a Fixed-Ratio Formulation of Basal Insulin Plus a GLP-1RA or to Basal Insulin Plus an SGLT2 Inhibitor: BEYOND, a Randomized, Pragmatic Trial

1361 Dasiglucagon—A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia: Results of Phase 3 Randomized Double-Blind Clinical Trial

Emerging Technologies: Data Systems and Devices

1368 Important Drop in Rate of Acute Diabetes Complications in People With Type 1 or Type 2 Diabetes After Initiation of Flash Glucose Monitoring in France: The RELIEF Study

Pathophysiology/Complications

1377 ACE I/D Polymorphism, Plasma ACE Levels, and Long-term Kidney Outcomes or All-Cause Death in Patients With Type 1 Diabetes

Cardiovascular and Metabolic Risk

1385 The Effect of Exenatide Once Weekly on Carotid Atherosclerosis in Individuals With Type 2 Diabetes: An 18-Month Randomized Placebo-Controlled Study
  J. Koska, R.Q. Migrino, K.C. Chan, K. Cooper-Cox, and P.D. Reaven

1393 Alcohol Abstinence and the Risk of Atrial Fibrillation in Patients With Newly Diagnosed Type 2 Diabetes Mellitus: A Nationwide Population-Based Study
1402 Autoantibodies Against Methylglyoxal-Modified Apolipoprotein B100 and ApoB100 Peptide Are Associated With Less Coronary Artery Atherosclerosis and Retinopathy in Long-Term Type 1 Diabetes

1410 Type 2 Diabetes Subtype Responsive to ACCORD Intensive Glycemia Treatment

1419 Biochemical Urine Testing of Medication Adherence and Its Association With Clinical Markers in an Outpatient Population of Type 2 Diabetes Patients: Analysis in the Diabetes and Lifestyle Cohort Twente (DiabetesCare 2021;44:1062–1069)

1426 Associations of Type 2 Diabetes Onset Age With Cardiovascular Disease and Mortality: The Kailuan Study
M. Zhao, L. Song, L. Sun, M. Wang, C. Wang, S. Yao, Y. Li, C. Yun, S. Zhang, Y. Sun, Z. Hou, S. Wu, and H. Xue

1433 Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study

Novel Communications in Diabetes

1443 Application of 2021 American Diabetes Association Glycemic Treatment Clinical Practice Recommendations in Primary Care
C. Colling, S.J. Atlas, and D.J. Wexler

1447 The Rapid Transition to Telemedicine and Its Effect on Access to Care for Patients With Type 1 Diabetes During the COVID-19 Pandemic

1451 Spike in Diabetic Ketoadsosisis Rates in Pediatric Type 2 Diabetes During the COVID-19 Pandemic
L.C. Chao, A.P. Vidmar, and S. Georgia

Errata

1454 Erratum. Clinical Translation of Cardiovascular Outcome Trials in Type 2 Diabetes: Is There More or Is There Less Than Meets the Eye? Diabetes Care 2021;44:641–646
E. Ferrannini and J. Rosenstock

1455 Erratum. Relations Between Subclinical Disease Markers and Type 2 Diabetes, Metabolic Syndrome, and Incident Cardiovascular Disease: The Jackson Heart Study Data. Diabetes Care 2015;38:1082–1088

H.L. Tanner, M. Dekker Nitert, L.K. Callaway, and H.L. Barrett

Icon icons show above appear on the first page of an article if more information is available online.

Video
Podcast
Supplementary Data
Companion Article

Issues and Events

1458 Issues and Events

e-Letters – Observations

e113 Is Shelter-in-Place Policy Related to Mail Order Pharmacy Use and Racial/Ethnic Disparities for Patients With Diabetes?

e115 Cysteinylated Albumin as a Potential Biomarker for the Progression of Kidney Disease in Patients With Type 2 Diabetes

e118 Performance of the Insulin-Only iLet Bionic Pancreas and the Bihormonal iLet Using Dasiglucagon in Adults With Type 1 Diabetes in a Home-Use Setting

e121 Inequity in Racial-Ethnic Representation in Randomized Controlled Trials of Diabetes Technologies in Type 1 Diabetes: Critical Need for New Standards
H.K. Akturk, S. Agarwal, L. Hoffecker, and V.N. Shah

e124 Capillary Ketone Concentrations at the Time of Colonoscopy: A Cross-Sectional Study With Implications for SGLT2 Inhibitor–Treated Type 2 Diabetes

e127 Cigarette Smoking as a Predictor of Sodium–Glucose Cotransporter 2 Inhibitor–Associated Genital Infections: A Retrospective Cohort Study
D. Scoccimarro, G. Cipani, I. Dicembrini, and E. Mannucci

e129 The Risks of Polycystic Ovary Syndrome and Diabetes Vary by Ethnic Subgroup Among Young Asian Women
L. Guo, N.P. Gordon, M. Chandra, O. Dayo, and J.C. Lo

e131 The Prevalence of Food Insecurity Is Highest Among Americans For Whom Diet Is Most Critical to Health
J.B. Kirby, D. Bernard, and L. Liang

e133 Temporal Trends in Lower-Limb Major and Minor Amputation and Revascularization Procedures in People With Diabetes in England During the COVID-19 Pandemic
J. Valabhji, E. Barron, E.P. Vamos, K. Dhatariya, F. Game, R. Kar, A. Weaver, S. Verma, B. Young, and K. Khunti

Cover: Light on the form of Green Tara. Credit: Jewelee. For more information, please visit istockphoto.com.
e-Letters – Comments and Responses

e136  Comment on Neeland et al. The Impact of Empagli flozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care 2020;43:3007–3015
S. Brikman and G. Dori

e137  Response to Comment on Neeland et al. The Impact of Empagli flozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care 2020;43:3007–3015
I.J. Neeland, T. Kasai, S.E. Inzucchi, B.S. Wojeck, H.K. Yaggi, and O.E. Johansen, on behalf of the EMPA-REG OUTCOME Investigators

e139  Comment on Vistisen et al. A Validated Prediction Model for End-Stage Kidney Disease in Type 1 Diabetes. Diabetes Care 2021;44:901–907
H.B. Østergaard, J. van der Leeuw, F.J. Visseren, and J. Westerink

e140  Response to Comment on Vistisen et al. A Validated Prediction Model for End-Stage Kidney Disease in Type 1 Diabetes. Diabetes Care 2021;44:901–907